title: In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary.
authors.forename: Michael
authors.initials: M
authors.lastname: Hutchinson
mesh_terms: D000284:Administration, Oral; D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007155:Immunologic Factors; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons